Evidence map›Paper›PMID 41158198›Full record

ArticleFrontiers in bioengineering and biotechnology2025

Retinal features as predictive indicators for high myopia: insights from explainable multi-machine learning models.

Haohan Zou, Jing Liu, Shenda Shi, Saiguang Ling, Qian Fan, Yan Huo, Zhou Dong, Guoge Han, Shengjin Wang, Yan Wang

Abstract read
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Haohan Zou *Tianjin Eye Hospital, Tianjin, China.
Jing Liu *Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Shenda ShiHuaHui Jian AI Tech Ltd., Tianjin, China.
Saiguang LingEVision technology (Beijing) Co., Ltd., Beijing, China.
Qian FanTianjin Eye Hospital, Tianjin, China.
Yan HuoTianjin Eye Hospital, Tianjin, China.
Zhou DongEVision technology (Beijing) Co., Ltd., Beijing, China.
Guoge HanTianjin Eye Hospital, Tianjin, China.
Shengjin WangHuaHui Jian AI Tech Ltd., Tianjin, China.
Yan WangTianjin Eye Hospital, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To investigate the role of retinal characteristics for high myopia (HM) prediction based on multi-machine learning (ML) and to provide an interpretable framework for the results. Methods: A total of 2981 patients (2981 eyes) were included, comprising 1191 HM eyes and 1790 non-HM eyes. A deep semantic segmentation network was used to quantify retinal structural parameters. Five ML algorithms were evaluated to develop predictive models, and SHapley Additive exPlanations method was applied to analyze feature contribution to the outcomes. Results: The eXtreme Gradient Boosting achieved an accuracy of 0.81 (95% confidence interval [CI] 0.78-0.85), and an area under the receiver operating characteristic curve of 0.87 (95% CI 0.84-0.89), outperforming other models. The 12 most important factors affecting prediction included tessellation density, seven vascular parameters, two parapapillary atrophy parameters, and two optic disc parameters. The tessellated density >0.025, width of parapapillary atrophy >400 um, parapapillary atrophy area >0.60 × 10 Conclusion: The XGBoost model outperformed other algorithms, and SHAP-derived cut-off values for critical risk factors enhanced clinical interpretability.

Indexed as

deep learninghigh myopiamachine learningretinal imaging omicsshapley additive exPlanation

Identifiers

PMID41158198
PMCPMC12555007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.